Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Natera Inc (NQ: NTRA )

105.47 +9.92 (+10.38%)
Streaming Delayed Price Updated: 12:49 PM EDT, May 10, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,078,510
Open 108.11
Bid (Size) 105.37 (2)
Ask (Size) 105.56 (6)
Prev. Close 95.55
Today's Range 101.02 - 108.31
52wk Range 36.90 - 98.82
Shares Outstanding 120,757,877
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Genpact Posts Upbeat Earnings, Joins Groupon, Natera, Funko, CarGurus And Other Big Stocks Moving Higher On Friday
Via Benzinga
Why Natera Is 'A Stock To Focus On' Following Its Mighty Beat-And-Raise
The company put up a "robust" beat and raise following an increase in test volume and sales prices in women's health and cancer detection. 
Via Investor's Business Daily

Performance

YTD
+70.32%
+70.32%
1 Month
+8.19%
+8.19%
3 Month
+51.42%
+51.42%
6 Month
+132.35%
+132.35%
1 Year
+105.95%
+105.95%

More News

Read More
Why Natera Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
How Is The Market Feeling About Natera?
Via Benzinga
Looking Into Natera's Recent Short Interest
Via Benzinga
Cracking The Code: Understanding Analyst Reviews For Natera
Via Benzinga
Looking Into Natera's Recent Short Interest
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Via InvestorPlace
US Stocks Set To End Week Strong With S&P 500 Eyeing Break Above Late-March Peak: Analyst Says He's Still A Buy In May Amid This Positive Signal
Via Benzinga
Topics Stocks
Exposures US Equities
Natera Inc. (NASDAQ: NTRA) Records 52-Week High Friday Morning
Via Investor Brand Network
Genomics Game-Changers: 3 Stocks Unlocking the Secrets of Life
Via InvestorPlace
NTRA Stock Earnings: Natera Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Natera Reports First Quarter 2024 Financial Results
From Natera, Inc.
Via Business Wire
New Natera Publication Bolsters Evidence for Extended Surveillance with Signatera™ in Breast Cancer
From Natera, Inc.
Via Business Wire
Natera to Report its First Quarter 2024 Results on May 9
From Natera, Inc.
Via Business Wire
Natera Launches Fetal RhD NIPT Supporting Ob/Gyn Physicians and Patients During RhIg Shortage
From Natera, Inc.
Via Business Wire
Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications
From Natera, Inc.
Via Business Wire
Natera Announces Publication of Largest Prospective dd-cfDNA Study in Kidney Transplantation
From Natera, Inc.
Via Business Wire
Natera Announces New Data From Two Studies Extending the Clinical Validation of Its Prospera™ Heart dd-cfDNA Test for Heart Transplant Recipients
From Natera, Inc.
Via Business Wire
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
From Natera, Inc.
Via Business Wire
Natera and Alliance for Clinical Trials in Oncology Announce Activation of Alliance A032103 (MODERN): A Randomized, Phase II/III Adjuvant Trial in Urothelial Cancer
From Natera, Inc.
Via Business Wire
Natera Announces Phase III Randomized CIRCULATE Trial in France, Evaluating Signatera™ in Stage II Colorectal Cancer
From Natera, Inc.
Via Business Wire
New KDIGO Guideline Supports Genetic Testing for the Majority of CKD Patients to Establish Cause of Disease
From Natera, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.